Companies:
49,824
Total Market Cap:
139401353162283.00
Global Rank
#6397
Country Rank
#30
Market Cap
1.9 B
Price
28.83
Change (%)
0.98%
Volume
147,602
Galapagos NV's latest marketcap:
1.9 B
As of 07/05/2025, Galapagos NV's market capitalization has reached $1.9 B. According to our data, Galapagos NV is the 6397th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.9 B |
| Revenue (ttm) | 311.49 M |
| Net Income (ttm) | -183,247,946 |
| Shares Out | 65.84 M |
| EPS (ttm) | -2.78 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/23/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Galapagos NV's yearly market capitalization.
Galapagos NV has seen its market value drop from $2.32 B to $1.9 B since 2015, representing a total decrease of 18.15% and an annual compound decline rate (CAGR) of 2.08%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $1.9 B | 4.83% | 6397 |
| 12/31/2024 | $1.81 B | -32.28% | 6079 |
| 12/29/2023 | $2.68 B | -8.14% | 4652 |
| 12/30/2022 | $2.91 B | -19.35% | 4114 |
| 12/31/2021 | $3.61 B | -43.56% | 4146 |
| 12/31/2020 | $6.4 B | -43.18% | 2344 |
| 12/31/2019 | $11.27 B | 141.07% | 1188 |
| 12/31/2018 | $4.67 B | 7.74% | 2146 |
| 12/29/2017 | $4.34 B | 72.91% | 2631 |
| 12/30/2016 | $2.51 B | 8.12% | 3366 |
Company Profile
Galapagos NV Overview
Galapagos NV is a biotechnology company specializing in the development of innovative medicines, with a primary focus on oncology and immunology. The company operates mainly in the United States and Europe.
Pipeline Products
- GLPG3667: Completed Phase 1b trial.
- GLPG5101: A CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma.
- GLPG5201: A CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory chronic lymphocytic leukemia.
- GLPG5301: A BCMA CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory multiple myeloma.
Collaborations
The company has strategic collaboration agreements with:
- Gilead Sciences, Inc.
- AbbVie S.à r.l.
Company Background
Founded in 1999, Galapagos NV is headquartered in Mechelen, Belgium.
Frequently Asked Questions
-
What is Galapagos NV's (GLPG) current market cap?As of 07/05/2025, Galapagos NV (including the parent company, if applicable) has an estimated market capitalization of $1.9 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Galapagos NV (GLPG) rank globally by market cap?Galapagos NV global market capitalization ranking is approximately 6397 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.